Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Holyoake

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Blood|June 1, 1996
Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrowT L Holyoake, M G Freshney, L McNair, et al.
Leukemia|May 13, 2005
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitroH G Jørgensen, E K Allan, S M Graham, et al.
Bone Marrow Transplantation|October 26, 2005
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT)M Cummins, K Cwynarski, S Marktel, et al.
Leukemia|March 6, 2009
A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic responseM W Drummond, N Heaney, J Kaeda, et al.
Clinical Pharmacology and Therapeutics|September 5, 2014
Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemiaA Davies, A Giannoudis, J E Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicityM J Alcorn, T L Holyoake, L Richmond, et al.
Bone Marrow Transplantation|January 11, 2005
A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patientsN E Jordanides, E K Allan, L A McLintock, et al.
Stem Cells (Dayton, Ohio)|October 1, 1993
Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitroT L Holyoake, M G Freshney, A M Sproul, et al.
Leukemia|August 28, 2009
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transportersA Davies, N E Jordanides, A Giannoudis, et al.
Blood Cancer Journal|July 26, 2012
Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cellsG Manzotti, S A Mariani, F Corradini, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Blood|June 1, 1996
Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrowT L Holyoake, M G Freshney, L McNair, et al.
Leukemia|May 13, 2005
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitroH G Jørgensen, E K Allan, S M Graham, et al.
Bone Marrow Transplantation|October 26, 2005
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT)M Cummins, K Cwynarski, S Marktel, et al.
Leukemia|March 6, 2009
A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic responseM W Drummond, N Heaney, J Kaeda, et al.
Clinical Pharmacology and Therapeutics|September 5, 2014
Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemiaA Davies, A Giannoudis, J E Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicityM J Alcorn, T L Holyoake, L Richmond, et al.
Bone Marrow Transplantation|January 11, 2005
A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patientsN E Jordanides, E K Allan, L A McLintock, et al.
Stem Cells (Dayton, Ohio)|October 1, 1993
Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitroT L Holyoake, M G Freshney, A M Sproul, et al.
Leukemia|August 28, 2009
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transportersA Davies, N E Jordanides, A Giannoudis, et al.
Blood Cancer Journal|July 26, 2012
Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cellsG Manzotti, S A Mariani, F Corradini, et al.
Pageof 7